Eli Lilly rises 2.32% as revenue guidance faces a quality-of-growth test
FROM THE WIRE · FINANCE.YAHOO.COM
This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) lifted its sales ambitionsand investors bid shares higher. The drugmaker raised its annual revenue forecast to $91 billion$92 billion in its October 29 results. Shares climbed 2.32% to $1,442.01 at 8:21 a.m. ET in…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA raised annual revenue forecast from a major drugmaker lifts the stock, though growth sustainability is questioned.AI-generated summary
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets